Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	176.33	115.85	118.37	234.2	118.72	147.7
Short-Term Investments	571.59	480.22	217.63	128.6	622.2	220.31
Cash & Short-Term Investments	747.92	596.07	336	362.79	740.92	368.01
Cash Growth	61.38%	77.40%	-7.38%	-51.03%	101.33%	-12.64%
Receivables	304.62	308.46	234.21	231.07	90.98	97.73
Inventory	164.87	141.86	127.6	100.12	53.91	60.75
Prepaid Expenses	44.62	38.95	48.61	45.02	40.48	28.27
Total Current Assets	1,262	1,085	746.42	739.01	926.29	554.76
Property, Plant & Equipment	72.82	75.04	74.94	75.57	8.79	10.59
Goodwill	416.82	416.82	416.82	409.05	-	-
Other Intangible Assets	384.07	401.83	472.88	546.65	-	-
Long-Term Deferred Tax Assets	5.19	3.86	4.39	44.43	155.43	-
Other Long-Term Assets	55.61	80.6	17.82	26.8	13.91	14.57
Total Assets	2,197	2,063	1,733	1,842	1,104	579.92
Accounts Payable	20.07	10.25	11.82	17.69	1.54	1.93
Accrued Expenses	130.31	121.8	100.68	97.66	22.17	19.08
Current Portion of Long-Term Debt	-	-	-	13.33	89.42	397.23
Current Portion of Leases	-	7.05	-	2.1	2.28	1.4
Current Unearned Revenue	-	-	-	-	1.75	1.75
Total Current Liabilities	150.38	139.1	112.49	130.79	117.15	421.39
Long-Term Debt	1,507	1,506	1,499	1,493	787.26	-
Long-Term Leases	29.39	23.65	32.2	32.69	0.54	3.47
Long-Term Unearned Revenue	-	-	-	-	2.53	4.03
Other Long-Term Liabilities	27.05	31.11	5.52	15.47	-	-
Total Liabilities	1,714	1,700	1,649	1,672	907.48	428.88
Common Stock	0.12	0.12	0.13	0.14	0.14	0.14
Additional Paid-In Capital	7.6	-	2.41	27.37	256.35	625.48
Retained Earnings	477.96	359.87	90.55	143.22	-58.91	-474.59
Comprehensive Income & Other	-3.41	3.83	-9.28	-0.92	-0.62	0.02
Shareholders' Equity	482.27	363.82	83.81	169.8	196.95	151.05
Total Liabilities & Equity	2,197	2,063	1,733	1,842	1,104	579.92
Total Debt	1,537	1,537	1,531	1,541	879.49	402.1
Net Cash (Debt)	-788.91	-940.43	-1,195	-1,178	-138.57	-34.08
Net Cash Per Share	-6.12	-7.27	-8.91	-8.38	-0.94	-0.24
Filing Date Shares Outstanding	123.22	123.15	126.82	135.37	137.7	135.21
Total Common Shares Outstanding	123.17	123.14	126.77	135.15	137.5	134.97
Working Capital	1,112	946.24	633.93	608.22	809.14	133.38
Book Value Per Share	3.92	2.95	0.66	1.26	1.43	1.12
Tangible Book Value	-318.62	-454.83	-805.89	-785.9	196.95	151.05
Tangible Book Value Per Share	-2.59	-3.69	-6.36	-5.81	1.43	1.12
Machinery	60.25	59.28	50.78	43.13	18.26	17.25
Leasehold Improvements	7.2	7.01	6.99	6.73	1.63	1.63
Order Backlog	-	99.9	-	-	-	-

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q